Prevention of new osteitis on magnetic resonance imaging in patients with early axial spondyloarthritis during 3 years of continuous treatment with etanercept: data of the ESTHER trial.

OBJECTIVE The aim of this study was to assess the degree of fluctuation of osteitis on MRI during long-term treatment with etanercept (ETN) in patients with early axial SpA (axSpA) with active inflammation (osteitis) on whole-body MRI in the spine and/or the SI joints at baseline. METHODS We analysed MRI data from 328 SI joint quadrants and 943 spine vertebral units (VUs) in terms of osteitis in the pooled data set of 41 patients who were treated with ETN for 3 consecutive years. Scoring was performed by two blinded radiologists at baseline, year 2 and year 3. RESULTS Through years 2 and 3, osteitis on MRI resolved completely in 56 of 144 (38.9%) SI joint quadrants and in 20 of 40 (50%) VUs affected at baseline, while persistent osteitis was found in 24 of 144 (16.7%) SI joint quadrants and in 8 of 40 (20.0%) spine VUs. The development of new osteitis in sites that were free of osteitis at baseline only occurred in 2 of 131 (1.5%) SI joint quadrants and in 3 of 862 (0.4%) spine VUs in both year 2 and year 3. CONCLUSION There was a consistently small amount of osteitis on MRI in patients with early axSpA compared with baseline values, and only a very low rate of new-onset osteitis was found during 3 years of continuous treatment with ETN. TRIAL REGISTRATION www.clinicaltrials.gov, NCT00844142.

[1]  A. Deodhar,et al.  Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study , 2012, Annals of the rheumatic diseases.

[2]  V. Mazurov,et al.  Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1 , 2013, Annals of the rheumatic diseases.

[3]  J. Braun,et al.  Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis , 2013, Annals of the rheumatic diseases.

[4]  J. Reveille,et al.  The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. , 2013, Arthritis and rheumatism.

[5]  D. M. van der Heijde,et al.  THU0431 Localisation of bone marrow edema in sacroiliac joints in spondyloarthritis patients: Does the site of lesions change over a 3-month period? , 2013 .

[6]  W. Maksymowych,et al.  Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification , 2012, Annals of the rheumatic diseases.

[7]  G. Burmester,et al.  Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial , 2012, Annals of the rheumatic diseases.

[8]  A. Deodhar,et al.  Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study , 2011, Annals of the rheumatic diseases.

[9]  A. Deodhar,et al.  Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study , 2011, Annals of the rheumatic diseases.

[10]  Andreas Krause,et al.  Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial , 2011, Annals of the rheumatic diseases.

[11]  M. Dougados,et al.  Arthritis 2 Spondyloarthritis , 2011 .

[12]  L. Coates,et al.  Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. , 2009, Arthritis and rheumatism.

[13]  J. Braun,et al.  Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes. , 2008, Arthritis and rheumatism.

[14]  P. Rahman,et al.  Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study. , 2007, Arthritis and rheumatism.

[15]  R. Landewé,et al.  Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. , 2006, Arthritis and rheumatism.

[16]  Jürgen Braun,et al.  Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. , 2006, Arthritis and rheumatism.

[17]  J. Braun,et al.  Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. , 2005, Rheumatology.

[18]  John C. Davis,et al.  Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor α receptor fusion protein etanercept , 2005 .